Postexposure prophylaxis for occupational exposure to HIV has its risks
Drug Reactions and Interactions
- 10 Downloads
KeywordsLamivudine Zidovudine Healthcare Worker Therapeutic Drug Monitoring Nevirapine
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 2.Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001; 50(RR11); 1–42Google Scholar
- 5.Fahrner R, Beekmann SE, Nelson L, et al. Combination post-exposure prophylaxis (PEP): a prospective study of HIV-exposed health care workers (HCW). 12th International Conference on AIDS; 1998 Jun 28–Jul 3; GenevaGoogle Scholar
- 7.Blanche S, Rouzioux C, Mandelbrot L, et al. Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission. 6th Annual Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31–Feb 4; ChicagoGoogle Scholar
- 8.Smyth AC. Important drug warning. Bristol-Myers Squibb Company. Available at: http://www.fda.gov/medwatch/safety/2001/pregwarnfinalbms.pdf [Accessed 2001 Mar 12]
- 9.British National Formulary. No. 41. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2001 MarGoogle Scholar
- 12.Wang SA, Puro V. Toxicity of post-exposure prophylaxis for human immunodeficiency virus. In: Panlilio L, editor. Balliere’s Clin Infect Dis. Vol 5. London: Balliere-Tindall, Inc, 1999: 349–63Google Scholar
- 15.Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures — worldwide, 1997–2000. MMWR 2001; 49(51): 1153–6Google Scholar
© Adis International Limited 2002